

CEMENT Q2FY25 Review 22 November 2024

## Seasonality hits performance; bright spots in H2FY25

 Volume driven by large companies; small, regional companies take a severe hit; realisation weakens 7% YoY on weak seasonal demand Milind Raginwar research@bobcaps.in

- Softer fuel cost continues to provide some respite EBITDA margins at 12.5% vs 16.3% QoQ, with aggregate fall in operating cost at ~2%
- Post results, we maintain our BUY rating for UTCEM, and SELL for JKLC and TRCL

Volume growth driven by big companies as prices weaken 7% YoY: Our cement universe volumes grew a listless 3% YoY on average in Q2FY25 driven by the large companies, while their regional small counterparts took a sharp hit. Seasonal demand weakness dragged demand. UTCEM's (capacity industry leader) volume grew 3% YoY despite its high base, while SRCM was the top gainer at 9%, followed by DALBHARA at 8%. Aggregate realisations fell ~7%/2% (YoY/QoQ) as cement demand was weak with cement prices falling further over Q1 average prices.

Cost savings offer limited respite: Our cement universe EBITDA margin grew on average by 12.4% in Q2FY25, down 400/310bps YoY/QoQ (16.3%/15.5%). ACEM led the pack with 17%, SRCM and STRCEM ~16%/15% and UTCEM ~13%. JKLC, ACC and ORCMNT saw below-average margins of ~5.4%/8.1%/9.3% respectively. Aggregate EBITDA/t fell by ~28%/23% YoY/QoQ to Rs 645 (Rs 897/Rs 840).

**Fuel & logistics costs continue to fall:** Fuel costs for our coverage fell by ~18% YoY on average led by softer pet coke prices. Logistics costs stayed flat at ~-1% as lead distance increased to chase volumes. Effectively, operating cost for our coverage fell ~1% YoY to Rs 4,644/t but inched up QoQ.

**Demand slowed in Q2FY25:** We note that cement demand was slower YoY as monsoon activity disruption was sharper (below normal in FY24), keeping construction activity below par. We stay optimistic on demand pickup in H2, aided by the government's infrastructure push, normal monsoons and improving rural mood. However, supply will keep pace with demand due to capacity additions, in our view.

**UTCEM** is our top pick: We maintain UTCEM's BUY rating (TP Rs 12,469) as we believe it is best placed to cater to expected demand growth with its large capacity, operational efficiencies, pan-India presence and balance sheet health. Maintain SELL rating on TRCL (Rs 726) and JKLC (Rs 661) due to continued weak show. We retain our HOLD ratings for JKCE (Rs 4,190), STRCEM (Rs 201) and SRCM (Rs 24,140). We drop coverage on ORCMNT (earlier SELL) on the acquisition by ACEM.





Fig 1 – Revenue growth

(Rs mn)	Q2FY25	Q2FY24	YoY (%)	Q1FY25	QoQ (%)	Comment
ACC	46,080	44,347	3.9	51,556	(10.6)	Aggregate revenue for our cement coverage fell
ACEM	42,132	39,698	6.1	45,158	(6.7)	by ~5% YoY in a very challenging quarter.
DALBHARA	30,870	31,490	(2.0)	36,210	(14.7)	by 3% for in a very challenging quarter.
JKCE	23,917	25,707	(7.0)	26,431	(9.5)	Volume gains, driven by large companies, were
JKLC	11,413	14,526	(21.4)	14,445	(21.0)	listless at mid-single digit. Realisations fell ~7%
ORCMNT	5,440	7,206	(24.5)	6,963	(21.9)	YoY as prices continued to fall sharply in the
SRCM	37,270	45,846	(18.7)	48,347	(22.9)	southern and eastern regions of India.
STRCEM	6,415	5,853	9.6	7,510	(14.6)	
TRCL	20,382	23,293	(12.5)	20,884	(2.4)	
UTCEM	1,49,052	1,55,170	(3.9)	1,75,324	(15.0)	
Aggregate	3,72,972	3,93,135	(5.1)	4,32,827	(13.8)	

Source: Company, BOBCAPS Research |

Fig 2 – EBITDA growth

(Rs mn)	Q2FY25	Q2FY24	YoY (%)	Q1FY25	QoQ (%)	Comment
ACC	4,292	5,484	(21.7)	6,772	(36.6)	<ul> <li>Aggregate EBITDA for our coverage fell ~24%</li> </ul>
ACEM	7,048	7,734	(8.9)	6,460	9.1	YoY. The decline would have been sharper but for
DALBHARA	4,340	6,690	(35.1)	5,890	(26.3)	some respite from energy cost savings.
JKCE	2,728	4,467	(38.9)	4,790	(43.1)	some respite from energy cost savings.
JKLC	613	1,785	(65.6)	1,846	(66.8)	<ul> <li>STRCEM posted healthy operating performance with only a 3% decline in EBITDA.</li> </ul>
ORCMNT	442	865	(48.9)	960	(53.9)	
SRCM	5,925	8,701	(31.9)	9,164	(35.3)	<ul> <li>JKLC/ORCMNT saw the sharpest fall at 66%/49%</li> </ul>
STRCEM	956	986	(3.0)	1,161	(17.7)	YoY, due to overall weak operating efficiencies.
TRCL	3,121	3,986	(21.7)	3,194	(2.3)	SRCM's fall in EBITDA was the highest among the
UTCEM	19,327	23,502	(17.8)	29,810	(35.2)	large cap companies
Aggregate	48,792	64,200	(24.0)	70,047	(30.3)	iargo oup companies

Source: Company, BOBCAPS Research

Fig 3 – Adj. PAT growth

(Rs mn)	Q2FY25	Q2FY24	YoY (%)	Q1FY25	QoQ (%)	Comment
ACC	2,339	3,843	(39.1)	3,662	(36.1)	Aggregate PAT for our coverage universe fell
ACEM	5,249	4,938	6.3	5,835	(10.0)	sharply by ~43% YoY compared to EBITDA on
DALBHARA	460	1,190	(61.3)	2,540	(81.9)	higher depreciation provisions and interest outgo
JKCE	452	1,789	(74.7)	2,027	(77.7)	following capacity expansion by most of the
JKLC	75	830	(90.9)	763	(90.1)	coverage companies.
ORCMNT	23	246	(90.6)	367	(93.7)	50751age 5077pa557
SRCM	931	4,913	(81.0)	3,177	(70.7)	
STRCEM	57	407	(86.1)	310	(81.7)	
TRCL	256	1,013	(74.7)	355	(27.9)	
UTCEM	7,969	12,057	(33.9)	16,758	(52.4)	
Aggregate	17,812	31,227	(43.0)	35,795	(50.2)	



Fig 4 – Volume growth

(mn tonnes)	Q2FY25	Q2FY24	YoY (%)	Q1FY25	QoQ (%)	Comment
ACC	9.3	8.1	14.8	10.2	(8.8)	LITCEM remains a steady volume driver even if
ACEM	8.7	7.6	14.5	9.3	(6.5)	<ul> <li>UTCEM remains a steady volume driver even if the base stayed high.</li> </ul>
DALBHARA	6.7	6.2	8.1	7.4	(9.5)	the base stayed high.
JKCE	4.2	4.3	(3.3)	4.7	(11.1)	SRCM's volume fell and came as a negative
JKLC	1.9	2.2	(14.0)	2.3	(19.8)	surprise as it switches between its focus on
ORCMNT	1.1	1.4	(23.4)	1.4	(19.5)	branding/premium category sales and volume
SRCM	7.6	8.2	(7.3)	9.6	(21.2)	push as in Q1FY25.
STRCEM	1.0	0.9	9.2	1.2	(15.3)	<ul> <li>Volume dip by JKCE was only 3% aided by capacity additions YoY, while STRCEM remains the star performer with ~9% volume growth in very challenging conditions.</li> </ul>
TRCL	4.5	4.6	(2.6)	4.4	3.0	
UTCEM	26.0	25.2	2.9	30.5	(14.7)	
Aggregate	70.9	68.8	3.1	80.9	(12.4)	

Source: Company, BOBCAPS Research

Fig 5 - Realisation per tonne

(Rs/t)	Q2FY25	Q2FY24	YoY (%)	Q1FY25	QoQ (%)	Comment
ACC	4,680	5,125	(8.7)	4,757	(1.6)	<ul> <li>Aggregate realisation for our coverage fell by ~7%</li> </ul>
ACEM	4,843	5,223	(7.3)	4,856	(0.3)	YoY indicating traditionally weak pricing in the Q2
DALBHARA	4,607	5,079	(9.3)	4,893	(5.8)	owing to strong monsoon affected by the overall
JKCE	5,693	5,919	(3.8)	5,595	1.8	weak infrastructure demand due to the delayed
JKLC	6,117	6,691	(8.6)	6,210	(1.5)	Union budget.  Q3 prices provide limited respite owing to the lack of construction activity due to the festive season.
ORCMNT	4,982	5,093	(2.2)	5,135	(3.0)	
SRCM	4,904	5,594	(12.3)	5,015	(2.2)	
STRCEM	6,560	6,532	0.4	6,508	0.8	
TRCL	4,539	5,053	(10.2)	4,790	(5.2)	
UTCEM	4,960	5,455	(9.1)	5,036	(1.5)	
Aggregate	5,189	5,576	(7.0)	5,279	(1.7)	

Source: Company, BOBCAPS Research

Fig 6 - Operating cost per tonne

(Rs/t)	Q2FY25	Q2FY24	YoY (%)	Q1FY25	QoQ (%)	Comment
ACC	4,493	4,179	7.5	4,391	2.3	Operating cost sovings helped to guard against a
ACEM	4,033	4,206	(4.1)	4,161	(3.1)	<ul> <li>Operating cost savings helped to guard against a sharper fall in EBITDA margin. Operating cost per</li> </ul>
DALBHARA	3,960	4,129	(4.1)	3,989	(0.7)	tonne for our coverage companies fell by 1%,
JKCE	5,044	4,890	3.1	4,581	10.1	driven by energy and logistics cost savings.
JKLC	5,788	5,869	(1.4)	5,417	6.8	anon by energy and legicited describerings.
ORCMNT	4,577	4,449	2.9	4,427	3.4	<ul> <li>However, prices reversed by 2% QoQ, indicating</li> </ul>
SRCM	4,124	4,533	(9.0)	4,065	1.5	the benefits of a higher cost base are waning
STRCEM	5,583	5,432	2.8	5,502	1.5	steadily.
TRCL	3,844	4,188	(8.2)	4,057	(5.2)	
UTCEM	4,995	5,217	(4.2)	4,777	4.6	
Aggregate	4,644	4,709	(1.4)	4,537	2.4	



Fig 7 - EBITDA per tonne

(Rs/t)	Q2FY25	Q2FY24	YoY (%)	Q1FY25	QoQ (%)	Comment
ACC	462	677	(31.8)	664	(30.5)	Aggregate earnings remained weak due to the
ACEM	810	1,018	(20.4)	695	16.6	EBITDA/t loss from the dent in realisations.
DALBHARA	621	923	(32.7)	877	(29.2)	EBIT DAY 1000 HOTH the delit in realisations.
JKCE	649	1,028	(36.9)	1,014	(36.0)	
JKLC	329	822	(60.0)	793	(58.6)	
ORCMNT	405	607	(33.3)	708	(42.8)	
SRCM	780	1,025	(23.9)	951	(18.0)	
STRCEM	977	1,100	(11.2)	1,006	(2.9)	
TRCL	673	843	(20.2)	710	(5.2)	
UTCEM	744	931	(20.1)	979	(24.0)	
Aggregate	645	897	(28.1)	840	(23.2)	


Source: Company, BOBCAPS Research

Logistics cost for our coverage dipped 1% YoY as the lead distance increased or stayed flat as companies chased long distance volume in a weak quarter

DALBHARA, JKCE and STRCEM's costs rose sharply by 8-10% while SRCM was the biggest beneficiary in 2Q


Fuel cost for our coverage companies dropped 18% YoY on softening pet coke prices. The benefits, however, will wane steadily on a lower base in the next few quarters

Fig 8 - Logistics cost per tonne



Source: Company, BOBCAPS Research

Fig 9 - Power & fuel cost per tonne






Average margin weakened 390bps YoY at 13% in Q2FY25. The fall was ~300bps QoQ, largely driven by weak pricing

UTCEM, SRCM and ACEM continued to have above-average gains

ORCMNT, JKLC and JKCE's margins stayed below par


Margins fell as cost savings offer only marginal respite in offsetting the dent in realisations in Q2FY25

Fig 10 - EBITDA margin



Source: Company, BOBCAPS Research

Fig 11 - Realisations vs. margins





# Fig 12 - Ongoing expansion projects

Company	Projects
ACC	Cement capacity
	Jodhpur Penna IU - 2mnt by Q3FY26
	Sankrail - 2.4mnt by Q4FY25
	Farakka - 2.4mnt by Q4FY25 (Phase 1)
	Sindri - 1.6mnt by Q4FY25
	Salai Banwa - 2.4mnt by Q1FY26
	Bathinda - 1.2mnt by Q2FY26
	<ul> <li>Marwar - 2.4mnt by Q2FY26</li> </ul>
	<ul> <li>Warishaliganj - 2.4mnt by Q4FY26</li> </ul>
ACEM	<ul> <li>Dahej Line 2 - 1.2mnt by Q3FY26</li> </ul>
	<ul> <li>Kalamboli - 1.0mnt by Q3FY26</li> </ul>
	<ul> <li>Krishnapatnam Penna - 2.0mnt by Q3FY26</li> </ul>
	Clinker capacity
	<ul> <li>Bhatapara Line 3mn-4mnt by Q4FY25</li> </ul>
	Maratha Line 2 - 4mnt by Q3FY26
	Jodhpur Penna IU - 3mnt by Q3FY26
	<ul> <li>ACEM spent Rs 35bn on capex in H1FY25 and expects to end FY25 with a capex of Rs 70bn-80bn.</li> </ul>
	Cement capacity
	<ul> <li>Kalyanpur, BH - 0.5mnt by H2FY25</li> </ul>
	<ul><li>Lanka, AS - 2.4mnt by H2FY25</li></ul>
DALBHARA	Clinker capacity
	<ul><li>Kadapa - 0.3mnt by H2FY25</li></ul>
	Rajgangpur - 0.6mnt by H2FY25
	<ul> <li>Umranghsu - 3.6mnt by FY26</li> </ul>
Heidelberg Cement	-
India Cement	-
	Cement capacity
	3mnt cement capacity at Panna, Hamirpur & Prayagraj (1MTPA at each location)
IVOE	3mnt split grinding unit at Bihar
JKCE	Clinker capacity
	<ul> <li>3.3 mnt grey clinker capacity at Panna, Schedule commissioning - December 2025</li> </ul>
	Capex guidance of Rs 18bn-20bn in FY25.
	Cement capacity
	<ul> <li>Surat grinding unit - 1.5mnt - end of FY25 (Rs 2.25bn)</li> </ul>
	<ul> <li>Durg, Chhattisgarh - 4.6mnt (FY27)</li> </ul>
	<ul> <li>Prayagraj (FY27), Madhubani (FY27), Patratu (FY28) - 3.4mnt.</li> </ul>
JKLC	Clinker capacity
	<ul> <li>Durg, Chhattisgarh - 2.3mnt (FY27)</li> </ul>
	<ul> <li>The Durg expansion project to cost Rs 25bn</li> </ul>
	<ul> <li>The Railway sliding project at Durg - Q1FY26 (Rs 3.25bn)</li> </ul>
	In H1, capex spent was Rs 1.75bn. Capex guidance for FY25 is Rs 5bn, with plans for Rs 7bn crores in FY26 and Rs 8bn-8.5bn in FY27.
ORCMNT	-
CDOM	Company and a site.
SRCM	Cement capacity



Company	Projects								
	<ul> <li>Jaitaran (Rajasthan) - 6mnt, Kodla (Karnataka) - 3mnt, Baloda Bazar (Chhattisgarh) ~3.4mnt, Etah (UP) - 3mnt expected to be completed by Q1FY26</li> </ul>								
	<ul> <li>Rs 18.60bn spent in H1FY25 and roughly Rs 40bn every year for the next four years</li> </ul>								
	Cement capacity								
	Silchar GU, Assam - 2mnt (FY26)								
0.70.0514	Jorhat GU, Assam - 2mnt (FY27)								
STRCEM	<ul> <li>800 CBM AAC block plant in Assam ~Dec 2024</li> </ul>								
	<ul> <li>Above 3 projects require a capex of Rs 12bn</li> </ul>								
	<ul> <li>Capex of Rs 6.50bn in FY25. Capex guidance for FY26 is Rs 4.50bn</li> </ul>								
	<ul> <li>The cement capacity increased from 23MTPA to 24MTPA in 2QFY25 through de-bottlenecking in Kolimigundla Integrated Unit and Salem Grinding Unit</li> </ul>								
TRCL	<ul> <li>On track to achieve cement capacity of 30MTPA by Mar'26 with the commissioning of the second line in Kolimigundla, along with de- bottlenecking of existing facilities/adding grinding capacities in existing locations with minimal capex</li> </ul>								
	<ul> <li>The capex estimated for FY25 remains at Rs 12bn</li> </ul>								
	Cement capacity								
	<ul> <li>Karur, Tamil Nadu - 0.6mnt by Q3FY25</li> </ul>								
	<ul> <li>Sonar Bangla, West Bengal - 0.6mnt by Q4FY25</li> </ul>								
	<ul> <li>Durgapur, West Bengal - 0.6mnt by Q4FY25</li> </ul>								
	<ul> <li>Maihar, Madhya Pradesh - 4.5mnt by Q4FY25</li> </ul>								
	<ul> <li>Lucknow, Uttar Pradesh - 1.8mnt by Q4FY25</li> </ul>								
	Panvel, Maharashtra - 1.0mnt by Q4FY25								
	<ul> <li>Patratu, Jharkhand - 2.5mnt by FY26</li> </ul>								
	<ul> <li>Shahjahanpur, Uttar Pradesh - 1.8mnt by FY26</li> </ul>								
	<ul> <li>Nathdwara, Rajasthan - 1.2mnt by FY26</li> </ul>								
UTCEM	<ul> <li>Dhule, Maharashtra - 1.8mnt by FY26</li> </ul>								
UTCEM	<ul> <li>Visakhapatnam, Andhra Pradesh - 3.3mnt by FY26</li> </ul>								
	Parli, Maharashtra- 1.2mnt by FY26								
	<ul> <li>Aligarh, Uttar Pradesh - 2.7mnt by FY27</li> </ul>								
	Bihar - 3.3mnt by FY27								
	<ul> <li>West Bengal - 3.3mnt by FY27</li> </ul>								
	<ul> <li>APCW, Andhra Pradesh - 2.7mnt by FY27</li> </ul>								
	Andhra Pradesh - 2.7mnt by FY2								
	Gujarat - 1.2mnt by FY27								
	Kamataka - 1.2mnt by FY27								
	<ul> <li>Assam - 1.2mnt by FY27</li> </ul>								
	Tamil Nadu - 1.8mnt by FY27								

Source: Company, BOBCAPS Research | GU: Grinding Unit; IU: Integrated Unit; WHRS: Waste heat recovery systems, mnt: million tonnes



NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

## **Disclaimer**

Name of the Research Entity: BOB Capital Markets Limited

Registered office Address: 1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051

SEBI Research Analyst Registration No: INH000000040 valid till 03 February 2025

Brand Name: BOBCAPS

Trade Name: www.barodaetrade.com CIN: U65999MH1996GOI098009

Logo:



Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

### Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%

HOLD - Expected return from -6% to +15%

SELL - Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

#### **Analyst certification**

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

#### General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.



#### Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

#### Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "Losses") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

### Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd) ("MSL") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "MAYBANK"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

### No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

### Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.